Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Buse

Endocrinology, Diabetes & Metabolism Chapel Hill, NC Medical Doctor

NPI 1336164680 CMS profile 151275

101 Manning Dr, Chapel Hill, NC 27599

Open in the dashboard

General payments

$459,508

329 records reported · program years 2019–2025

Research payments

$6,303

Paid to them · 12 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,315,498 paid to institutions, not to them · program years 2019–2025

Through program year 2025, John Buse of Chapel Hill, NC is reported in the CMS Open Payments database as having received $459,508 across 329 general payments and $6,303 in research payments paid to them. Separately, studies naming them as principal investigator received $3,315,498 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $87,608 52
2025 Research $500 1
2024 General $69,014 73
2023 General $41,456 62
2023 Research $1,771 7
2022 General $56,357 40
2022 Research $2,750 1
2021 General $54,625 18
2020 General $49,736 35
2019 General $100,712 49
2019 Research $1,283 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Buse
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to John Buse were reported at $87,608. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year John Buse Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $100,712 $494 $123–$2,253 $163
2020 $49,736 $335 $85–$1,841 $114
2021 $54,625 $398 $88–$1,981 $132
2022 $56,357 $364 $88–$1,568 $149
2023 $41,456 $420 $113–$1,614 $160
2024 $69,014 $440 $121–$1,646 $164
2025 $87,608 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk AS $157,757 53 payments
  2. Novo Nordisk Inc $81,149 38 payments
  3. Eli Lilly and Company $57,776 81 payments
  4. AstraZeneca Pharmaceuticals LP $33,723 34 payments
  5. Corcept Therapeutics $27,401 21 payments
  6. Vertex Pharmaceuticals Incorporated $18,073 38 payments
  7. CeQur Corporation $14,129 3 payments
  8. Mannkind Corporation $9,717 12 payments
  9. Recordati_Rare_Diseases_Inc. $9,136 7 payments
  10. Boehringer Ingelheim International GmbH $8,500 2 payments
  11. Other $42,147 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $322,195 103 payments
  2. Travel and Lodging $60,449 125 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $53,732 27 payments
  4. Honoraria $17,010 3 payments
  5. Food and Beverage $4,579 68 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $1,488 2 payments
  7. Education $56 1 payment
Products named General payments · program years 2019–2025
  1. Korlym $27,401 21 payments
  2. Victoza $16,337 7 payments
  3. CeQur Simplicity $14,129 3 payments
  4. RYBELSUS $12,010 7 payments
  5. AFREZZA $9,586 11 payments
  6. OSILODROSTAT $9,136 7 payments
  7. JARDIANCE $8,500 2 payments
  8. Xultophy 100/3.6 $8,206 7 payments
  9. Saxenda $7,995 2 payments
  10. Dasiglucagon $3,750 1 payment
  11. Other $15,729 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novo Nordisk AS $3,250 2 payments
  2. Corcept Therapeutics $1,771 7 payments
  3. Sanofi-Aventis U.S. LLC $1,283 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

1,221

Median for Endocrinology: 1,959

Drug cost

$523,929

Median for Endocrinology: $890,201

Branded share of claims

43.2%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 92 $180,098
Jardiance Empagliflozin Brand 66 $94,973
Mounjaro Tirzepatide Brand 50 $85,910
Tresiba Flextouch U-200 Insulin Degludec Brand 19 $62,117
Tresiba Flextouch U-100 Insulin Degludec Brand 41 $34,340
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 20 $16,462
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 30 $10,237
Farxiga Dapagliflozin Propanediol Brand 12 $8,192
Novolog Flexpen Insulin Aspart Brand 15 $4,526
Humalog Kwikpen U-100 Insulin Lispro Brand 12 $3,802

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$11,006

Medicare's payments for the services billed

Medicare patients

56

Average age 72

Services billed

248

26 women, 30 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 52%
Chronic kidney disease 48%
Ischemic heart disease 46%
Depression 27%
Heart failure 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Victoza
  • Novo Nordisk AS $13,669
$13,669 — —
Korlym
  • Corcept Therapeutics $10,097
$10,097 — —
MOUNJARO
  • Eli Lilly and Company $456
$456 50 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

341 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record